Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion (CRM010)
Ability of Androgen-receptor Blockade to Normalize Progesterone-induced Augmentation of Gonadotropin Secretion in PCOS (CRM010)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Melissa Gilrain, BS
- Phone Number: 4342436911
- Email: pcos@virginia.edu
Study Contact Backup
- Name: Christopher M McCartney, MD
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22901
- Recruiting
- University of Virginia
-
Contact:
- Melissa Gilrain, BS
- Phone Number: 434-243-6911
- Email: pcos@virginia.edu
-
Contact:
- Christopher M McCartney, MD
- Phone Number: 434-243-6911
- Email: cm2hq@virginia.edu
-
Principal Investigator:
- Christopher M McCartney, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Post-pubertal (> 4 years post-menarche) adult woman aged 18-30 years
- PCOS, defined as clinical and/or laboratory evidence of hyperandrogenism (hirsutism and/or elevated serum [calculated] free testosterone concentration) plus ovulatory dysfunction (irregular menses, fewer than 9 per year), but without evidence for other potential causes of hyperandrogenism and/or ovulatory dysfunction
- General good health (excepting overweight, obesity, hyperandrogenism, PCOS, and adequately-treated hypothyroidism)
- Capable of and willing to provide informed consent
- Willing to strictly avoid pregnancy with use of reliable non-hormonal methods during the study period
Exclusion Criteria:
- Inability/incapacity to provide informed consent
- Males will be excluded (PCOS is unique to females)
- Age < 18 years or > 30 years (ovarian reserve may decrease beyond age 30)
- Obesity resulting from a well-defined endocrinopathy or genetic syndrome
- Positive pregnancy test or current lactation
- Evidence for non-physiologic or non-PCOS causes of hyperandrogenism and/or anovulation
- Evidence of virilization (e.g., rapidly progressive hirsutism, deepening of the voice, clitoromegaly)
- Total testosterone > 150 ng/dl, which suggests the possibility of virilizing ovarian or adrenal tumor
- DHEA-S elevation > 1.5 times the upper reference range limit. Mild elevations may be seen in PCOS, and will be accepted in these groups
- Early morning 17-hydroxyprogesterone > 200 ng/dl measured in the follicular phase, which suggests the possibility of congenital adrenal hyperplasia (if elevated during the luteal phase, the 17-hydroxyprogesterone will be repeated during the follicular phase). NOTE: If a 17-hydroxyprogesterone > 200 ng/dl is confirmed on repeat testing, an ACTH stimulated 17-hydroxyprogesterone < 1000 ng/dl performed by the subject's personal physician will be required for study participation.
- Abnormal thyroid stimulating hormone (TSH): Note that subjects with stable and adequately treated primary hypothyroidism, reflected by normal TSH values, will not be excluded.
- Hyperprolactinemia > 20% higher than the upper limit of normal. Mild prolactin elevations may be seen in women with PCOS, and elevations within 20% higher than the upper limit of normal will be accepted in this group.
- History and/or physical exam findings suggestive of Cushing's syndrome, adrenal insufficiency, or acromegaly
- History and/or physical exam findings suggestive of hypogonadotropic hypogonadism (e.g., symptoms of estrogen deficiency) including functional hypothalamic amenorrhea (which may be suggested by a constellation of symptoms including restrictive eating patterns, excessive exercise, psychological stress, etc.)
- Persistent hematocrit < 37% and hemoglobin < 12 g/dl
- Severe thrombocytopenia (platelets < 50,000 cells/microliter) or leukopenia (total white blood count < 4,000 cells/microliter)
- Previous diagnosis of diabetes, fasting glucose > or = 126 mg/dl, or a hemoglobin A1c > or = 6.5%
- Given that this study involves flutamide use, any liver panel abnormality will be grounds for exclusion
- Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure, asthma requiring intermittent systemic corticosteroids, etc.)
- Decreased renal function evidenced by GFR < 60 ml/min/1.73m2
- A personal history of breast, ovarian, or endometrial cancer
- History of allergy to micronized progesterone, flutamide, or transdermal estradiol
- BMI < 18 or > 40 kg/m2
- Due to the amount of blood being drawn, volunteers with body weight < 110 pounds must be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Prior to the first or the second admission (randomly determined), participants will be pretreated for 2 weeks with placebo (twice daily).
|
Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.
oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
Other Names:
Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
Other Names:
|
|
Experimental: Flutamide
Prior to the first or second admission (randomly determined), subjects will be pretreated for 4 weeks with Flutamide (250 mg twice daily)
|
oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission
Other Names:
Flutamide, 250 mg taken orally twice daily for four weeks before study admission.
Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean FSH concentration with progesterone administration
Time Frame: After 4 weeks of placebo administration
|
Change in mean FSH concentrations (post-progesterone FSH concentrations vs. pre-progesterone FSH concentrations)
|
After 4 weeks of placebo administration
|
|
Change in mean FSH concentration with progesterone administration
Time Frame: After 4 weeks of flutamide administration
|
Change in mean FSH concentrations (post-progesterone FSH concentrations vs. pre-progesterone FSH concentrations)
|
After 4 weeks of flutamide administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean LH concentration with progesterone administration
Time Frame: After 4 weeks of placebo administration
|
Change in mean LH concentrations (post-progesterone LH concentrations vs. pre-progesterone LH concentrations)
|
After 4 weeks of placebo administration
|
|
Change in mean LH concentration with progesterone administration
Time Frame: After 4 weeks of flutamide administration
|
Change in mean LH concentrations (post-progesterone LH concentrations vs. pre-progesterone LH concentrations)
|
After 4 weeks of flutamide administration
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Christopher M McCartney, MD, Univsersity of Virginia
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Endocrine System Diseases
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Polycystic Ovary Syndrome
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Estrogens
- Hormone Antagonists
- Androgen Antagonists
- Progestins
- Estradiol
- Progesterone
- Flutamide
Other Study ID Numbers
Other Study ID Numbers
- HSR200016
- R01HD102060 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.